Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease

[1]  Jin-Moo Lee,et al.  Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ* , 2006, Journal of Biological Chemistry.

[2]  M. Staufenbiel,et al.  Neprilysin-sensitive Synapse-associated Amyloid-β Peptide Oligomers Impair Neuronal Plasticity and Cognitive Function* , 2006, Journal of Biological Chemistry.

[3]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[4]  L. Mucke,et al.  SIRT1 Protects against Microglia-dependent Amyloid-β Toxicity through Inhibiting NF-κB Signaling* , 2005, Journal of Biological Chemistry.

[5]  L. Mucke,et al.  Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[6]  Bertrand Z. Yeung,et al.  Vulnerability of Dentate Granule Cells to Disruption of Arc Expression in Human Amyloid Precursor Protein Transgenic Mice , 2005, The Journal of Neuroscience.

[7]  Katalin F Medzihradszky,et al.  Inhibition of cathepsin B reduces β-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate β-secretase of Alzheimer's disease , 2005, Biological chemistry.

[8]  Ilana S. Hairston,et al.  Environmental Enrichment Reduces Aβ Levels and Amyloid Deposition in Transgenic Mice , 2005, Cell.

[9]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[10]  L. Mucke,et al.  Intracellularly generated amyloid‐β peptide counteracts the antiapoptotic function of its precursor protein and primes proapoptotic pathways for activation by other insults in neuroblastoma cells , 2004, Journal of neurochemistry.

[11]  J. Buxbaum,et al.  Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome , 2004, Neurobiology of Aging.

[12]  L. Mucke,et al.  Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation , 2004, Nature Medicine.

[13]  Dominic M. Walsh,et al.  Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.

[14]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[15]  Ann-Shyn Chiang,et al.  Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: A potential model for Alzheimer's disease , 2004 .

[16]  C. Almeida,et al.  Oligomerization of Alzheimer's β-Amyloid within Processes and Synapses of Cultured Neurons and Brain , 2004, The Journal of Neuroscience.

[17]  L. Gan,et al.  Identification of Cathepsin B as a Mediator of Neuronal Death Induced by Aβ-activated Microglial Cells Using a Functional Genomics Approach* , 2004, Journal of Biological Chemistry.

[18]  H. Mizukami,et al.  Presynaptic Localization of Neprilysin Contributes to Efficient Clearance of Amyloid-β Peptide in Mouse Brain , 2004, The Journal of Neuroscience.

[19]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[20]  H. Mori,et al.  Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form , 2003, Neuroscience Letters.

[21]  Jacob Raber,et al.  Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. Gage,et al.  Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice , 2003, The Journal of Neuroscience.

[23]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[24]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[25]  S. Yasothornsrikul,et al.  β‐Amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for β‐secretase activity in chromaffin vesicles , 2002, Journal of neurochemistry.

[26]  A. LeBlanc,et al.  Selective cytotoxicity of intracellular amyloid β peptide1–42 through p53 and Bax in cultured primary human neurons , 2002, The Journal of cell biology.

[27]  D. Selkoe.  Clearing the Brain's Amyloid Cobwebs , 2001, Neuron.

[28]  C. Eckman,et al.  Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme* , 2001, The Journal of Biological Chemistry.

[29]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Saido,et al.  Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.

[31]  J. Kos,et al.  Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. , 2001, Biochemical and biophysical research communications.

[32]  L. Mucke,et al.  TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice , 2001, Nature Medicine.

[33]  D. Comings,et al.  Molecular heterosis: a review. , 2000, Molecular genetics and metabolism.

[34]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[35]  A. Sher,et al.  Analysis of Fractalkine Receptor CX3CR1 Function by Targeted Deletion and Green Fluorescent Protein Reporter Gene Insertion , 2000, Molecular and Cellular Biology.

[36]  S. Scheff,et al.  The Plasmin System Is Induced by and Degrades Amyloid-β Aggregates , 2000, The Journal of Neuroscience.

[37]  D. Selkoe,et al.  Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme , 2000, The Journal of Neuroscience.

[38]  A. Bell,et al.  Negative Regulation of Epidermal Growth Factor Signaling by Selective Proteolytic Mechanisms in the Endosome Mediated by Cathepsin B* , 1999, The Journal of Biological Chemistry.

[39]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[40]  Bonnie F. Sloane,et al.  Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. , 1999, European journal of biochemistry.

[41]  J. Sloane,et al.  Metalloendopeptidase EC 3.4.24.15 Is Necessary for Alzheimer’s Amyloid-β Peptide Degradation* , 1999, The Journal of Biological Chemistry.

[42]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  L. Hersh,et al.  Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.

[44]  P. Greengard,et al.  Generation and Regulation of β‐Amyloid Peptide Variants by Neurons , 1998 .

[45]  G. Cole,et al.  Protease Inhibitor Coinfusion with Amyloid β-Protein Results in Enhanced Deposition and Toxicity in Rat Brain , 1998, The Journal of Neuroscience.

[46]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Deussing,et al.  Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  R. Ménard,et al.  Major increase in endopeptidase activity of human cathepsin B upon removal of occluding loop contacts. , 1997, Biochemistry.

[49]  R. Nixon,et al.  Increased Neuronal Endocytosis and Protease Delivery to Early Endosomes in Sporadic Alzheimer’s Disease: Neuropathologic Evidence for a Mechanism of Increased β-Amyloidogenesis , 1997, The Journal of Neuroscience.

[50]  C. Guenet,et al.  A possible role for cathepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer's disease. , 1997, European journal of biochemistry.

[51]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[52]  T Vernet,et al.  Role of the Occluding Loop in Cathepsin B Activity* , 1997, The Journal of Biological Chemistry.

[53]  M. Yano,et al.  Autocatalytic inactivation of lysosomal cathepsins is associated with inhibition of protein breakdown by insulin-like growth factor-1 (IGF-1) in myotubes. , 1995, Biochemical and biophysical research communications.

[54]  Bonnie F. Sloane,et al.  Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. , 1992, The Biochemical journal.

[55]  Robert Huber,et al.  The refined 2.15 A X‐ray crystal structure of human liver cathepsin B: the structural basis for its specificity. , 1991, The EMBO journal.

[56]  R. Ménard,et al.  A model to explain the pH-dependent specificity of cathepsin B-catalysed hydrolyses. , 1991, The Biochemical journal.

[57]  R. Nixon,et al.  Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[58]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Goerke,et al.  Unilamellar liposomes made with the French pressure cell: a simple preparative and semiquantitative technique. , 1980, Journal of lipid research.

[60]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[61]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[62]  F. LaFerla,et al.  A dynamic relationship between intracellular and extracellular pools of Abeta. , 2006, The American journal of pathology.

[63]  Nobuhisa Iwata,et al.  Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. , 2005, Nature medicine.

[64]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[65]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[66]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[67]  S. Scheff,et al.  The Plasmin System Is Induced by and Degrades Amyloid-b Aggregates , 2000 .

[68]  H. Chapman,et al.  Emerging roles for cysteine proteases in human biology. , 1997, Annual review of physiology.

[69]  R.,et al.  Amyloid precursor protein processing and Ab42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[70]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.